SWOG clinical trial number
SWOG-8796

Combination Chemotherapy for Advanced Hodgkin's Disease

Closed
Phase
Published
Abbreviated Title
Combination Chemotherapy for Advanced Hodgkin's Disease
Activated
12/01/1987
Closed
08/01/1989

Research committees

Lymphoma

Publication Information Expand/Collapse

1998

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year result of the intergroup trial.

JH Glick;ML Young;D Harrington;RL Schilsky;T Beck;R Neiman;RI Fisher;BA Peterson;MM Oken Journal of Clinical Oncology 16(1):19-26

1991

A randomized phase III trial of MOPP/ABV Hybrid vs. sequential MOPP-ABVD in advanced Hodgkin's disease: Preliminary results of the intergroup trial.

J Glick;A Tsiatis;R Schilsky;T Beck;M Oken;B Peterson;R Fisher ASCO 10:271(#941)

Other Clinical Trials

SWOG Clinical Trial Number
S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
74%
Open
Phase